Heteroaryls and uses thereof

A compound of formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
• when Y2 is C, R1 is H, —CN, halogen, —Z—R3, C1-6 aliphatic, or 3-10-membered cycloaliphatic, wherein:
• Z is selected from an optionally substituted C1-3 alkylene chain, —O—, —S—, —S(O)—, —S(O)2—, —C(O)—, —CO2—, —C(O)NR1a—, —N(R1a)C(O)—, —N(R1a)CO2—, —S(O)2NR1a—, —N(R1a)S(O)2—, —OC(O)N(R1a)—, —N(R1a)C(O)NR1a—, —N(R1a)S(O)2N(R1a)—, or —OC(O)—;
• R1a is hydrogen or an optionally substituted C1-4 aliphatic, and
• R3 is an optionally substituted group selected from C1-6 aliphatic, 3-10-membered cycloaliphatic, 4-10-membered heterocyclyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 6-10-membered aryl, or 5-10-membered heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• R2 is H, halogen, —W—R5, or —R5, wherein:
• W is selected from an optionally substituted C1-3 alkylene chain, —O—, —N(R2a)—, —S—, —S(O)—, —S(O)2—, —C(O)—, —CO2—, —C(O)NR2a—, —N(R2a)C(O)—, —N(R2a)CO2—, —S(O)2NR2a—, —N(R2a)S(O)2—, —OC(O)N(R2a)—, —N(R2a)C(O)NR2a—, —N(R2a)S(O)2N(R2a)—, or —OC(O)—,
• R2a is hydrogen or an optionally substituted C1-4aliphatic, and
• R5 is an optionally substituted group selected from C1-4 aliphatic, 3-10-membered cycloaliphatic, 4-10-membered heterocyclyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 6-10-membered aryl, or 5-10-membered heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• X1, X2, and X3 are each independently N or CR6, wherein each occurrence of R6 is independently hydrogen, —CN, halogen, —V—R7, C1-6aliphatic, or 3-10-membered cycloaliphatic, wherein:
• V is selected from an optionally substituted C1-3 alkylene chain, —O—, —N(R6a)—, —S—, —S(O)—, —S(O)2—, —C(O)—, —CO2—, —C(O)NR6a—, —N(R6a)C(O)—, —N(R6a)CO2—, —S(O)2NR6a—, —N(R6a)S(O)2—, —OC(O)N(R6a)—, —N(R6a)C(O)NR6a—, N(R6a)S(O)2N(R6a)—, or —OC(O)—,
• R6a is hydrogen or an optionally substituted C1-4 aliphatic, and
• R7 is an optionally substituted group selected from C1-6 aliphatic, 3-10-membered cycloaliphatic, 4-10-membered heterocyclyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 6-10-membered aryl, or 5-10-membered heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• Y1 is S, O, NR8, wherein R8 is hydrogen or an optionally substituted C1-4aliphatic;
• Y2 is C, N
• CY is
• wherein each occurrence of R4 is independently —R4a or -T1-R4d, wherein:
• each occurrence of R4a, as valency and stability permit, is independently fluorine, ═O, ═S, —CN, —NO2, —R4c, —N(R46)2, —OR4b, —SR4c, —S(O)2R4c, —C(O)R4b, —C(O)OR4b, —C(O)N(R4b)2, —S(O)2N(R4b)2, —OC(O)N(R4b)2, —N(R4e)C(O)R4b, —N(R4e)SO2R4c, —N(R4e)C(O)OR4b, —N(R4e)C(O)N(R4b)2, or —N(R4e)SO2N(R4b)2, or two occurrences of R4b, taken together with a nitrogen atom to which they are bound, form an optionally substituted 4-7-membered heterocyclyl ring having 0-1 additional heteroatoms selected from nitrogen, oxygen, or sulfur;
• each occurrence of R4b is independently hydrogen or an optionally substituted group selected from C1-C6 aliphatic, 3-10-membered cycloaliphatic, 4-10-membered heterocyclyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 6-10-membered aryl, or 5-10-membered heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• each occurrence of R4c is independently an optionally substituted group selected from C1-C6aliphatic, 3-10-membered cycloaliphatic, 4-10-membered heterocyclyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 6-10-membered aryl, or 5-10-membered heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• each occurrence of R4d is independently hydrogen or an optionally substituted from 3-10-membered cycloaliphatic, 4-10-membered heterocyclyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 6-10-membered aryl, or 5-10-membered heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• each occurrence of R4e is independently hydrogen or an optionally substituted C1-6aliphatic group;
• and
• T1 is an optionally substituted C1-C6alkylene chain wherein the alkylene chain optionally is interrupted by —N(R4a)—, —O—, —S—, —S(O)—, —S(O)2—, —C(O)—, —C(O)O—, —C(O)N(R4a)—, —S(O)2N(R4a)—, —OC(O)N(R4a)—, —N(R4a)C(O)—, —N(R4a)SO2—, —N(R4a)C(O)O—, —NR4a C(O)N(R4a)—, —N(R4a)S(O)2N(R4a)—, —OC(O)—, or —C(O)N(R4a)—O— or wherein T1 or a portion thereof optionally forms part of an optionally substituted 3-7 membered cycloaliphatic or heterocyclyl ring;
• n is 0-6;
• m is 1 or 2;
• p is 0, 1, or 2;
• represents a single or double bond;
• and
• provided that the compound of formula I is other than Morpholine, 4-[5-(4,5-diphenyl-1H-imidazol-2-yl)-2-thienyl]-.